Ensysce Biosciences receives Nasdaq delisting notice for equity shortfall

Ensysce Biosciences, Inc.

Notice received August 20, 2024; non-compliance with $2.5 million stockholders' equity minimum as of June 30, 2024.
Company plans to timely request a hearing before the Nasdaq Hearings Panel, which will stay delisting action.
No assurance that the Panel will grant continued listing or that compliance can be shown before any extension expires.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.